Inogen Q3 revenue falls on lower international sales
INGN•Inogen's third-quarter revenue fell 2.4% year over year to $77.2 million, while adjusted loss was $0.02 per share. The company launched a $20 million cost-reduction program, raised its share buyback authorization to $45 million and forecast full-year 2026 revenue of $298 million to $301 million.
1. Quarterly results
Inogen's third-quarter revenue fell 2.4% year over year to $77.2 million. Adjusted loss per share from continuing operations was $0.02, compared with adjusted earnings of $0.04 per share a year earlier. Gross margin was 44.1%.
2. Sales drivers and plans
U.S. sales grew 3.8%, driven by demand for portable oxygen concentrators and new products, partly offset by softness in international markets. Lower international sales weighed on revenue and gross margin. Inogen launched a $20 million cost-reduction program and raised its share buyback authorization to $45 million.
3. 2026 outlook
The company expects fourth-quarter 2026 revenue from continuing operations of $65 million to $68 million and full-year revenue of $298 million to $301 million. It forecasts a full-year adjusted loss from continuing operations of $7 million to $8 million.
